Glioblastoma model mouse rescue from mortality by brain-targeted catalytically-enhanced angiotensin-converting enzyme 2 mutant-antibody fusion protein
We have discovered that an engineered angiotensin-converting enzyme 2 (ACE2)-brain-targeted antibody fusion protein, referred to as ACE2dm-s1, improves survival of CT-2A xenograft glioblastoma (GBM) model mice when administered in combination with a small molecule STING agonist cancer therapeutic. Particularly striking about these survival results is that prior efforts that used losartan, a small…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
